bioAffinity Technologies Reports Record 300% Surge in CyPath® Lung Sales for April

summarizeSummary

bioAffinity Technologies announced record monthly unit sales for its CyPath® Lung diagnostic test in April, with nearly 300% year-over-year growth, providing a crucial operational boost amidst ongoing financial challenges and a short cash runway.

check_boxKey Events

• Record Monthly Sales Achieved

  Unit sales for the CyPath® Lung diagnostic test reached a record high in a single month during April 2026, based on preliminary unaudited data.

• Significant Year-Over-Year Growth

  April 2026 unit sales increased by nearly 300% compared to the same period in 2025, continuing the accelerating adoption trend seen in Q1 2026.

• CEO Highlights Accelerating Adoption

  President and CEO Maria Zannes noted that CyPath® Lung usage continues to accelerate rapidly as its value in lung cancer diagnosis is increasingly recognized by physicians.

• Operational Strength Amidst Financial Need

  This strong operational performance provides a positive counterpoint to the company's recently disclosed going concern warning and critical cash runway through June 2026, potentially aiding future financing efforts.

auto_awesomeAnalysis

This filing reports a significant acceleration in sales for the company's flagship diagnostic product, CyPath® Lung. The nearly 300% year-over-year growth in April unit sales, following a 146% increase in Q1, demonstrates strong operational momentum. This positive news is critical for bioAffinity Technologies, which recently disclosed a going concern warning and a cash runway extending only through June 2026. Sustained sales growth could improve the company's position in securing much-needed financing to extend its operational runway.